{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:31Z","timestamp":1793325751295,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["F\/050065\/01-02\/X32"],"award-info":[{"award-number":["F\/050065\/01-02\/X32"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Age- and height-adjusted total kidney volume is currently considered the best prognosticator in patients with autosomal dominant polycystic kidney disease. We tested the ratio of urinary epidermal growth factor and monocyte chemotactic peptide 1 for the prediction of the Mayo Clinic Imaging Classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Urinary epidermal growth factor and monocyte chemotactic peptide 1 levels were measured in two independent cohorts (discovery,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200974 and validation set,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009177) and healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200959) by immunological assay. Magnetic resonance imaging parameters were used for total kidney volume calculation and the Mayo Clinic Imaging Classification defined slow (1A\u20131B) and fast progressors (1C\u20131E). Microarray and quantitative gene expression analysis were used to test epidermal growth factor and monocyte chemotactic peptide 1 gene expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline ratio of urinary epidermal growth factor and monocyte chemotactic peptide 1 correlated with total kidney volume adjusted for height (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u00a00.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), estimated glomerular filtration rate (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.69\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), discriminated between Mayo Clinic Imaging Classes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and predicted the variation of estimated glomerular filtration rate at 10\u00a0years (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u00a00.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Conditional Inference Trees identified cut-off levels of the ratio of urinary epidermal growth factor and monocyte chemotactic peptide 1 for slow and fast progressors at\u2009&gt;\u2009132 (100% slow) and\u2009&lt;\u200925.76 (89% and 86% fast, according to age), with 94% sensitivity and 66% specificity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20096.51E\u221216). Further, the ratio of urinary epidermal growth factor and monocyte chemotactic peptide 1 at baseline showed a positive correlation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.36) with renal outcome (delta-estimated glomerular filtration rate per year, over a mean follow-up of 4.2\u2009\u00b1\u20091.2\u00a0years). Changes in the urinary epidermal growth factor and monocyte chemotactic peptide 1 were mirrored by gene expression levels in both human kidney cysts (epidermal growth factor: \u2212\u00a05.6-fold, fdr\u2009=\u20090.001; monocyte chemotactic peptide 1: 3.1-fold, fdr\u2009=\u20090.03) and\n                      <jats:italic>Pkd1<\/jats:italic>\n                      knock-out mouse kidney (\n                      <jats:italic>Egf<\/jats:italic>\n                      : \u2212\u00a014.8-fold, fdr\u2009=\u20092.37E-20,\n                      <jats:italic>Mcp1<\/jats:italic>\n                      : 2.8-fold, fdr\u2009=\u20096.82E\u221215).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ratio of urinary epidermal growth factor and monocyte chemotactic peptide 1 is a non-invasive pathophysiological biomarker that can be used for clinical risk stratification in autosomal dominant polycystic kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01468-w","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:02:47Z","timestamp":1667779367000},"page":"987-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Urinary epidermal growth factor\/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease"],"prefix":"10.1093","volume":"36","author":[{"given":"Maria Teresa","family":"Rocchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Matino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ighli","family":"di Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Trepiccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Capolongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Khowaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Stefano","family":"Netti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-0911","authenticated-orcid":false,"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"(Studio PRE. MED. (MEDicina di PREcisione) Prog.n.F\/050065\/01-02\/X32)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"1468_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PCPY (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"1468_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/imj.13143","volume":"46","author":"GK Rangan","year":"2016","unstructured":"Rangan GK, Tchan MC, Tong A et al (2016) Recent advances in autosomal-dominant polycystic kidney disease. Intern Med J 46:883\u2013892. https:\/\/doi.org\/10.1111\/imj.13143","journal-title":"Intern Med J"},{"key":"1468_CR3","doi-asserted-by":"publisher","unstructured":"Cordido A, Besada-cerecedo L, Garc\u00eda-gonz\u00e1lez MA (2017) The genetic and cellular basis of autosomal dominant polycystic kidney disease\u2014a primer for clinicians. 5:1\u20138. https:\/\/doi.org\/10.3389\/fped.2017.00279","DOI":"10.3389\/fped.2017.00279"},{"key":"1468_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0114-5","author":"C Woon","year":"2015","unstructured":"Woon C, Bielinski-bradbury A, Reilly KO, Robinson P (2015) A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-015-0114-5","journal-title":"BMC Nephrol"},{"key":"1468_CR5","doi-asserted-by":"publisher","unstructured":"Irazabal M V, Rangel LJ, Bergstralh EJ, et al (2015) Imaging classi fi cation of autosomal dominant polycystic kidney disease\u202f: a simple model for selecting patients for clinical trials. 160\u2013172. https:\/\/doi.org\/10.1681\/ASN.2013101138","DOI":"10.1681\/ASN.2013101138"},{"key":"1468_CR6","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1172\/JCI72272","volume":"124","author":"PTV Harris","year":"2014","unstructured":"Harris PTV (2014) Genetic mechanisms and signaling pathways in autosomal dominant polycytic kidney disease. J Clin Invest 124:2315\u20132324","journal-title":"J Clin Invest"},{"key":"1468_CR7","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1172\/JCI80467","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Zhou X, Fan LX et al (2015) Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest 125:2399\u20132412","journal-title":"J Clin Invest"},{"key":"1468_CR8","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1681\/ASN.2018050518","volume":"29","author":"MF Cassini","year":"2018","unstructured":"Cassini MF, Kakade VR, Kurtz E, Sulkowski P, Glazer P, Torres R, Somlo SCL (2018) Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 29:2471\u20132481","journal-title":"J Am Soc Nephrol"},{"key":"1468_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00266763","volume":"96","author":"EC Salido","year":"1991","unstructured":"Salido EC, Lakshmanan J, Fisher DA, Shapiro LJBL (1991) Expression of epidermal growth factor in the rat kidney. An immunocytochemical and in situ hybridization study. Histochemistry 96:65\u201372","journal-title":"Histochemistry"},{"key":"1468_CR10","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND et al (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18:2328\u20132343. https:\/\/doi.org\/10.1093\/hmg\/ddp165","journal-title":"Hum Mol Genet"},{"key":"1468_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1681\/ASN.2011010084","volume":"22","author":"A Karihaloo","year":"2011","unstructured":"Karihaloo A, Koraishy F, Huen SC et al (2011) Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22:1809\u20131814","journal-title":"J Am Soc Nephrol"},{"key":"1468_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000424404","volume":"115","author":"L Gesualdo","year":"1995","unstructured":"Gesualdo L, Petrarulo F, Pallotta G, Tricarico G, Ranieri ESF (1995) Urinary epidermal growth factor concentration in patients affected by ADPKD. Contrib Nephrol 115:105\u2013108","journal-title":"Contrib Nephrol"},{"key":"1468_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","volume":"3","author":"AL Messchendorp","year":"2018","unstructured":"Messchendorp AL, Meijer E, Boertien WE et al (2018) Urinary biomarkers to identify autosomal. Kidney Int Rep 3:291\u2013301. https:\/\/doi.org\/10.1016\/j.ekir.2017.10.004","journal-title":"Kidney Int Rep"},{"key":"1468_CR14","doi-asserted-by":"publisher","unstructured":"Zheng D, Wolfe M, Cowley BD, et al (2003) Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. 2588\u20132595. https:\/\/doi.org\/10.1097\/01.ASN.0000088720.61783.19","DOI":"10.1097\/01.ASN.0000088720.61783.19"},{"key":"1468_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.ki.5002621","volume":"73","author":"DD Torres","year":"2008","unstructured":"Torres DD, Rossini M, Manno C et al (2008) The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73:327\u2013333. https:\/\/doi.org\/10.1038\/sj.ki.5002621","journal-title":"Kidney Int"},{"key":"1468_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","volume":"47","author":"WN Leonhard","year":"2019","unstructured":"Leonhard WN, Song X, Kanhai AA, Iliuta IA, Bozovic A, Steinberg GR et al (2019) Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47:436\u2013445. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041","journal-title":"EBioMedicine"},{"key":"1468_CR17","unstructured":"Hothorn TZA (2015) \u201cpartykit: a modular toolkit for recursive partytioning in R.\u201d J Mach Learn Res 16:3905\u20133909. https:\/\/jmlr.org\/papers\/v16\/hothorn15a.html."},{"key":"1468_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ki.1996.94","volume":"49","author":"L Gesualdo","year":"1996","unstructured":"Gesualdo L, Di Paolo S, Calabr\u00f3 A, Milani S, Maiorano E, Ranieri E, Pannarale GFPS (1996) Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 49:656\u2013665","journal-title":"Kidney Int"},{"key":"1468_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7071","author":"W Ju","year":"2015","unstructured":"Ju W, Nair V, Smith S et al (2015) Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aac7071","journal-title":"Sci Transl Med"},{"key":"1468_CR20","doi-asserted-by":"publisher","unstructured":"Harskamp LR, Gansevoort RT, Boertien WE, et al (2015) Urinary EGF receptor ligand excretion in patients with autosomal dominant polycystic kidney disease and response to tolvaptan. 1\u20138. https:\/\/doi.org\/10.2215\/CJN.09941014","DOI":"10.2215\/CJN.09941014"},{"key":"1468_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/HYPERTENSIONAHA.108.113860","volume":"52","author":"WB Melenhorst","year":"2008","unstructured":"Melenhorst WB, Mulder GM, Xi Q, Hoenderop JG, Kimura K, Eguchi S, van Goor H (2008) Epidermal growth factor receptor signaling in the kidney: Key roles in physiology and disease. Hypertension 52:987\u2013993","journal-title":"Hypertension"},{"key":"1468_CR22","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1681\/ASN.V371378","volume":"3","author":"T Nakamura","year":"1993","unstructured":"Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Nagao S, Takahashi H, Koide H (1993) Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3:1378\u20131386. https:\/\/doi.org\/10.1681\/ASN.V371378","journal-title":"J Am Soc Nephrol"},{"key":"1468_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1159\/000452595","volume":"41","author":"S Worawichawong","year":"2016","unstructured":"Worawichawong S, Worawichawong S, Radinahamed P et al (2016) Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as biomarkers for interstitial fibrosis and tubular atrophy in primary glomerulonephritis. Kidney Blood Press Res 41:997\u20131007. https:\/\/doi.org\/10.1159\/000452595","journal-title":"Kidney Blood Press Res"},{"key":"1468_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000369149","volume":"129","author":"C Zoja","year":"2015","unstructured":"Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M, Zanchi C, Buelli S, Guglielmotti A, Perico N, Andrea Remuzzi GR (2015) Effects of MCP1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron 129:52\u201361. https:\/\/doi.org\/10.1159\/000369149","journal-title":"Nephron"},{"key":"1468_CR25","doi-asserted-by":"crossref","unstructured":"Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE T 3:4 I (2017) Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transpl 32:969\u2013975","DOI":"10.1093\/ndt\/gfw060"},{"key":"1468_CR26","first-page":"99","volume":"64","author":"NA Kirby","year":"2014","unstructured":"Kirby NA, Stepanek AM, Vernet A et al (2014) Urinary MCP1 and microalbumin increase prior to onset of azotemia in mice with polycystic kidney disease. Comp Med 64:99\u2013105","journal-title":"Comp Med"},{"key":"1468_CR27","doi-asserted-by":"publisher","unstructured":"Segarra-Medrano A, Martin MAI, et al. (2020) Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease. Clin Kidney J 13:607\u2013612. https:\/\/doi.org\/10.1093\/ckj\/sfz105","DOI":"10.1093\/ckj\/sfz105"},{"key":"1468_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0211212","volume":"14","author":"S Meybosch","year":"2019","unstructured":"Meybosch S, De Monie A, Ann\u00e9 C et al (2019) Epidermal growth factor and its influencing variables in healthy children and adults. PLoS One 14:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0211212","journal-title":"PLoS One"},{"key":"1468_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2018.01.015","volume":"104","author":"E Chanrat","year":"2018","unstructured":"Chanrat E, Worawichawong S, Radinahamed P et al (2018) Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors of complete remission in primary glomerulonephritis. Cytokine 104:1\u20137. https:\/\/doi.org\/10.1016\/j.cyto.2018.01.015","journal-title":"Cytokine"},{"key":"1468_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"EC Gall","year":"2015","unstructured":"Gall EC, Audr\u00e9zet M-P, Rousseau A et al (2015) The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:1\u201310. https:\/\/doi.org\/10.1681\/ASN.2015010016","journal-title":"J Am Soc Nephrol"},{"key":"1468_CR31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone RD, Mouksassi MS, Romero K et al (2017) Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2:442\u2013450. https:\/\/doi.org\/10.1016\/j.ekir.2017.01.003","journal-title":"Kidney Int Rep"},{"key":"1468_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2015.01.030","volume":"66","author":"A Alam","year":"2015","unstructured":"Alam A, Dahl NK, Lipschutz JH et al (2015) Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy. Am J Kidney Dis 66:564\u2013576. https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.030","journal-title":"Am J Kidney Dis"},{"key":"1468_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2215\/CJN.10470620","volume":"16","author":"JE Heida","year":"2021","unstructured":"Heida JE, Gansevoort RT, Messchendorp AL et al (2021) Use of the urine-to-plasma urea ratio to predict ADPKD progression. Clin J Am Soc Nephrol 16:204\u2013212. https:\/\/doi.org\/10.2215\/CJN.10470620","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01468-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:09Z","timestamp":1777564389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/4\/987\/8304772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01468-w","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was carried out in accordance with the Helsinki Declaration (IV Adaptation) and the European Guidelines for Good Clinical Practice. The study protocol was approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria Consorziale Policlinico of Bari, Italy (Authorization nr. 0065; 22 January 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}